Novartis' fully human monoclonal antibody, ianalumab (VAY736), has triumphantly met its primary endpoints in both global Phase III clinical trials, NEPTUNUS-1 and NEPTUNUS-2, signifying a pivotal advancement in the management of Sjögren's syndrome. Leveraging a dual mechanism of action specifically targeting B cells, this drug showcases promising therapeutic benefits not only for Sjögren's syndrome but also for other autoimmune conditions. Trial findings indicate that ianalumab can markedly reduce disease activity in patients, positioning it as a potential pioneering targeted therapy for Sjögren's syndrome. Novartis intends to present detailed data at forthcoming medical conferences and submit marketing applications to pertinent regulatory bodies. Sjögren's syndrome, a prevalent yet frequently overlooked autoimmune disease, currently lacks effective systemic treatments, and the successful development of ianalumab is poised to bridge this critical gap.